[1] Sung H, Ferlay J, Siegel RL, et al.  Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.   doi: 10.3322/caac.21660
[2] Herbst RS, Morgensztern D, Boshoff C.  The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.   doi: 10.1038/nature25183
[3] Kim ES, Kish JK, Cseh A, et al.  Second-line Afatinib or chemotherapy following immunochemotherapy for the treatment of metastatic, squamous cell carcinoma of the lung: real-world effectiveness and safety from a multisite retrospective chart review in the USA[J]. Clin Lung Cancer, 2021, 22(4): 292-300.e1.   doi: 10.1016/j.cllc.2021.02.006
[4] Chen YQ, Yang Y, Ma LB, et al.  Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma[J]. Eur J Radiol, 2019, 112: 44-51.   doi: 10.1016/j.ejrad.2019.01.005
[5] Rami-Porta R, Asamura H, Travis WD, et al.  Lung cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J]. CA Cancer J Clin, 2017, 67(2): 138-155.   doi: 10.3322/caac.21390
[6] Sequist LV, Han JY, Ahn MJ, et al.  Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study[J]. Lancet Oncol, 2020, 21(3): 373-386.   doi: 10.1016/S1470-2045(19)30785-5
[7] 中国抗癌协会肺癌专业委员会, 中华医学会肿瘤学分会肺癌学组, 中国胸部肿瘤研究协作组.  Ⅰ~ⅢB期非小细胞肺癌完全切除术后辅助治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(16): 1132-1142.   doi: 10.3760/cma.j.cn112137-20210210-00406
Lung Cancer Professional Committee of Chinese Anti-Cancer Association, Lung Cancer Group of Chinese Medical Association Oncology Branch, China Thoracic Cancer Research Collaboration Group.  Guidelines for adjuvant therapy after complete resection of stage Ⅰ -ⅢB non-small cell lung cancer (2021)[J]. J China Med, 2021, 101(16): 1132-1142.   doi: 10.3760/cma.j.cn112137-20210210-00406
[8] Mei DD, Luo Y, Wang Y, Gong JS.  CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses[J]. Cancer Imaging, 2018, 18(1): 52-.   doi: 10.1186/s40644-018-0184-2
[9] Tu WT, Sun GY, Fan L, et al.  Radiomics signature: a potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology[J]. Lung Cancer, 2019, 132: 28-35.   doi: 10.1016/j.lungcan.2019.03.025
[10] 娄和南, 赵晓丹, 张亮, 等.  周围型浸润性肺腺癌EGFR基因突变与CT征象及病理的相关性[J]. 实用放射学杂志, 2016, 32(12): 1856-1860.   doi: 10.3969/j.issn.1002-1671.2016.12.009
Lou HN, Zhao XD, Zhang L, et al.  Correlation of CT features and pathological characteristics with EGFR gene mutations in invasive peripheral pulmonary adenocarcinoma[J]. J Pract Radiol, 2016, 32(12): 1856-1860.   doi: 10.3969/j.issn.1002-1671.2016.12.009
[11] Shi YK, Au JSK, Thongprasert S, et al.  A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)[J]. J Thorac Oncol, 2014, 9(2): 154-162.   doi: 10.1097/JTO.0000000000000033
[12] 何小群, 李琦, 罗天友, 等.  临床、病理特征联合能谱CT评估非小细胞肺癌表皮生长因子受体基因突变[J]. 中国医学影像技术, 2021, 37(2): 230-234.   doi: 10.13929/j.issn.1003-3289.2021.02.015
He XQ, Li Q, Luo TY, et al.  Clinical, pathological and spectral CT characteristics in evaluation on epidermal growth factor receptor gene mutation of non-small cell lung cancer[J]. Chin J Med Imaging Technol, 2021, 37(2): 230-234.   doi: 10.13929/j.issn.1003-3289.2021.02.015
[13]

金晶. 肺腺癌18F-FDG PET/CT影像表现与EGFR基因突变的相关性分析及其在预后评估中的价值[D]. 青岛: 青岛大学, 2018.

Jin J. Correlation between 18F-FDG PET/CT imaging and EGFR gene mutation and the prognostic value of the metabolic parameters in patients with lung adenocarcinoma[D]. Qingdao: Qingdao University, 2018.
[14] Gao XC, Wei CH, Zhang RG, et al.  18F-FDG PET/CT SUVmax and serum CEA levels as predictors for EGFR mutation state in Chinese patients with non-small cell lung cancer[J]. Oncol Lett, 2020, 20(4): 61-.   doi: 10.3892/ol.2020.11922
[15] Yang Y, Yang Y, Zhou X, et al.  EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity[J]. Lung Cancer, 2015, 87(3): 272-277.   doi: 10.1016/j.lungcan.2014.12.016
[16] Liu Y, Kim J, Qu FY, et al.  CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma[J]. Radiology, 2016, 280(1): 271-280.   doi: 10.1148/radiol.2016151455
[17] 陈志红, 赵雪梅, 叶元滋, 等.  肺腺癌EGFR突变与病理组织学亚型及CT影像学特征的关系[J]. 临床与实验病理学杂志, 2021, 37(4): 469-472.   doi: 10.13315/j.cnki.cjcep.2021.04.022
Chen ZH, Zhao XM, Ye YZ, et al.  The relationship between EGFR mutations and histopathological subtypes and CT imaging features in lung adenocarcinoma[J]. Chin J Clin Exp Pathol, 2021, 37(4): 469-472.   doi: 10.13315/j.cnki.cjcep.2021.04.022
[18] Han XY, Fan J, Gu J, et al.  CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas[J]. Cancer Imaging, 2020, 20(1): 51-.   doi: 10.1186/s40644-020-00330-1
[19] 梁明玉.  非小细胞肺癌临床和影像特征与表皮生长因子受体的相关性[J]. 实用放射学杂志, 2021, 37(3): 503-506.   doi: 10.3969/j.issn.1002-1671.2021.03.041
Liang MY.  Correlation between epidermal growth factor receptor and clinical and imaging features of non-small cell lung cancer[J]. J Pract Radiol, 2021, 37(3): 503-506.   doi: 10.3969/j.issn.1002-1671.2021.03.041
[20] 阮磊, 夏聪, 李俊, 等.  非小细胞肺癌CT征象肿瘤标记物与EGFR基因突变的相关性研究[J]. 浙江临床医学, 2020, 22(1): 17-19.
Ruan L, Xia C, Li J, et al.  The correlation of CT signs, tumor markers and EGFR gene mutation in non-small cell lung cancer[J]. Zhejiang Clin Med J, 2020, 22(1): 17-19.
[21] 陈妍, 余莹莹, 文智, 等.  肺腺癌高分辨率CT特征及组织病理学与EGFR基因状态的相关性分析[J]. 实用放射学杂志, 2021, 37(9): 1433-1436, 1475.   doi: 10.3969/j.issn.1002-1671.2021.09.008
Chen Y, Yu YY, Wen Z, et al.  Correlation of high resolution CT features and histopathology with EGFR gene status in lung adenocarcinoma[J]. J Pract Radiol, 2021, 37(9): 1433-1436, 1475.   doi: 10.3969/j.issn.1002-1671.2021.09.008